Abstract
To determine the efficacy of an interferon alpha and ribavirin combination treatment for Japanese patients infected with hepatitis C virus (HCV) of genotype 2, a multi-center study was retrospectively analyzed. In total, 173 patients with HCV genotype 2 started to receive interferon-alpha subcutaneously thrice a week and 600-800 mg of ribavirin daily for 24 wk. The overall sustained virological response (SVR), defined as undetectable HCV RNA in serum, 24 wk after the end of treatment, was remarkably high by 84.4%, (146/173) by an intention-to-treat analysis. A significant difference in SVR was found between patients with and without the discontinuation of ribavirin (46.9% vs 92.9%), but no difference was found between those with and without a dose reduction of ribavirin. A significant difference in SVR was also found between patients with less than 16 wk and patients with 16 or more weeks of ribavirin treatment (34.8% vs 92.0%). The 24-wk interferon and ribavirin treatment is highly effective for Japanese patients with HCV genotype 2. The significant predictor of SVR is continuation of the ribavirin treatment for up to 16 weeks.
References
Jul 1, 1994·Journal of Medical Virology·G PozzatoG Santini
Nov 1, 1993·The Journal of General Virology·P SimmondsM S Urdea
Dec 17, 1997·Journal of Clinical Microbiology·J A NevilleP Simmonds
Jan 28, 1998·Clinical Therapeutics·N FurusyoS Kashiwagi
Feb 4, 1998·Archives of Internal Medicine·J HayashiS Kashiwagi
Nov 10, 1998·Lancet·T PoynardJ Albrecht
Nov 20, 1998·The New England Journal of Medicine·J G McHutchisonJ K Albrecht
Jul 3, 1999·Science·V LohmannR Bartenschlager
Oct 26, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T PoynardJ Albrecht
Jul 7, 2001·The New England Journal of Medicine·G M Lauer, B D Walker
Aug 2, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K L LindsayUNKNOWN Hepatitis Interventional Therapy Group
Oct 5, 2001·Lancet·M P MannsJ K Albrecht
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Aug 27, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Gary L DavisJanice Albrecht
Nov 26, 2003·The American Journal of Gastroenterology·John B WongUNKNOWN International Hepatitis Interventional Therapy Group
Jan 16, 2004·Gastroenterology·Takanobu KatoTakaji Wakita
May 4, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hideyuki NomuraSeizaburo Kashiwagi
Oct 16, 2004·Journal of Gastroenterology and Hepatology·Hideyuki NomuraHiromi Ishibashi
Nov 24, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Olav DalgardHelge Bell
May 26, 2005·Antiviral Research·Norihiro FurusyoJun Hayashi
Citations
Sep 3, 2013·Hepatitis Research and Treatment·Shinji ShimodaJun Hayashi
Apr 20, 2010·BMC Gastroenterology·Eiichi OgawaJun Hayashi
Jun 9, 2009·Haemophilia : the Official Journal of the World Federation of Hemophilia·M RahmaniF Ala
May 6, 2016·Hepatitis Monthly·Mohammad PouryasinAli Pouryasin
May 10, 2017·Journal of Medical Virology·Maissa El RazikyRasha M H Shahin
May 15, 2012·Endocrine·Kyoko OkadaJun Hayashi
Feb 18, 2016·Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology·Nader NemrMohamed Mandour
Nov 23, 2011·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Mosaburo KainumaUNKNOWN Kyushu University Liver Disease Study (KULDS) Group
Jul 5, 2007·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Norihiro FurusyoJun Hayashi
Feb 6, 2008·Journal of Gastroenterology and Hepatology·Norihiro FurusyoUNKNOWN Kyushu University Liver Disease Study (KULDS) Group
Jul 5, 2007·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Eiichi OgawaJun Hayashi